Scancell
A sweet source of financingScancell
SCIB1 Phase II study starts in UKScancell
Ground prepared for an important periodScancell
Vulpes investment brings £3.88m in new fundsScancell
SCIB2 to use new nanoparticle formulationScancell
Phase II melanoma study with SCIB1 to start in Q219Scancell
Interim results show progress being maintainedScancell
Missing out on the CRUK Grand ChallengeScancell
Opening new pathways in immuno-oncology